Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Employees - 183,
CEO - Dr. Laura E. Niklason M.D., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 800.63M
Altman ZScore(max is 10): -10.01, Piotroski Score(max is 10): 3, Working Capital: $2063000, Total Assets: $114764000, Retained Earnings: $-665075000, EBIT: -139652000, Total Liabilities: $178485000, Revenue: $10790000
AryaFin Target Price - $0.21 - Current Price $4.64 - Analyst Target Price $13.43
Ticker | HUMA |
Index | RUT |
Curent Price | 4.64 |
Change | 34.10% |
Market Cap | 800.63M |
Average Volume | 4.25M |
Income | -152.87M |
Sales | 0.00M |
Book Value/Share | -0.53 |
Cash/Share | 0.12 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 183 |
Moving Avg 20days | 8.83% |
Moving Avg 50days | -4.39% |
Moving Avg 200days | -14.52% |
Shares Outstanding | 119.84M |
Earnings Date | Nov 08 BMO |
Inst. Ownership | 27.90% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | - |
Price/Book | - |
Price/Cash | 38.66 |
Price/FCF | - |
Quick Ratio | 1.10 |
Current Ratio | 1.10 |
Debt/Equity | - |
Return on Assets | -115.74% |
Return on Equity | -850.81% |
Return on Investment | - |
Gross Margin | - |
Ops Margin | - |
Profit Margin | - |
RSI | 53.53 |
BETA(β) | 1.36 |
From 52week Low | 87.10% |
From 52week High | -53.46% |
EPS | -1.34 |
EPS next Year | -0.86 |
EPS next Qtr | -0.25 |
EPS this Year | -26.44% |
EPS next 5 Year | - |
EPS past 5 Year | - |
Sales past 5 Year | 0.00% |
EPS Y/Y | -54.99% |
Sales Y/Y | -100.00% |
EPS Q/Q | -30.64% |
Sales Q/Q | - |
Sales Surprise | - |
EPS Surprise | -32.48% |
ATR(14) | 0.58 |
Perf Week | 13.17% |
Perf Month | 5.22% |
Perf Quarter | -11.28% |
Perf Year | 69.34% |
Perf YTD | 63.38% |
Target Price | 13.43 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer